On February 25, 2020, Thousand Oaks Biopharmaceuticals Co., Ltd. and Beijing Biocytogen Co., Ltd. ("Biocytogen") reached an intention of strategic cooperation. The tie-up is a powerful combination between a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) and a Chinese distinctive antibody drug R&D, cooperation and service company.
Biocytogen provides one-stop new drug R&D cooperation and services for biopharmaceutical customers worldwide, ranging from drug target to IND application. By using RenMabTM Mouse for high-throughput humanized antibody preparation, and target humanized mouse models for IVD efficacy evaluation, Biocytogen has established a unique high-efficiency and large-scale antibody drug R&D platform in the industry. Biocytogen cooperates with more than 70% of the world's Top 50 pharmaceutical companies and many biotech companies to accelerate the speed and efficiency of new drug development, pool efforts to discover innovative drugs, and meet medical needs of patients better, thereby contributing to the better health of the mankind. “We chose Thousand Oaks Biopharmaceuticals Co., Ltd. as a partner for pre-clinical drug development for its excellent technical capabilities,” said Dr Yuelei Shen, Chairman and CEO of Biocytogen. “The company has served more than 100 customers from China and abroad, and among the pre-clinical research projects it had undertaken, many had been successfully approved in the IND applications to FDA (the U.S.) and NMPA (China). As the first Chinese serum-free cell culture media (CCM) supplier, JSBiosciences, a subsidiary of Thousand Oaks Biopharmaceuticals Co., Ltd., is a well-deserved leader in China in terms of either the number of customers or the production capacity. Therefore, I am rather optimistic about our cooperation. In 2020, we will have at least 20 pre-clinical development projects for Thousand Oaks Biopharmaceuticals Co., Ltd.!"
“We feel honored and privileged to get engaged into Biocytogen's early phase drug research projects." Dr Shun Luo, Chairman and President at Thousand Oaks Biopharmaceuticals Co., Ltd., said, “Biocytogen is internationally renowned for its genetically modified animals new drug development platform. It cooperates with more than 70% of the world's Top 50 pharmaceutical companies and many biotech companies, and performs antibody drug development for at least a hundred targets each year. As a leading company of CMC in China, Thousand Oaks Biopharmaceuticals Co., Ltd. integrates industrial resources to provide customers with total solutions for scale production in compliance with regulatory requirements. I believe our platforms and technologies, rich CDMO business experience can guarantee and accelerate the clinical and commercial progress of drugs in the early phases! "
Biocytogen and Thousand Oaks Biopharmaceuticals Co., Ltd. are both located in the Haimen Biotech and Medicine Center (HMC) in Nantong, Jiangsu Province. Mr. Jun Xu, Vice Chairman of the Haimen CPPCC and Secretary of the Party Working Committee of Linjiang New District, extended his congratulations for the tie-up, "the center's main focus is the development of the bioengineering and pharmaceutical industry. It adopts innovative concepts, and has rolled out the incubation model of "industry + capital + platform”, successively invested and introduced many featured projects, such as Biocytogen and Thousand Oaks Biopharmaceuticals Co., Ltd., to build a bio-medical/pharmaceutical industry ecosystem, and successfully attracted a wealth of high-level innovative and entrepreneurial talent. Now the cooperation between Thousand Oaks Biopharmaceuticals Co., Ltd. and Biocytogen marks the closed loop of the industry within the center, which is quite in line with the original intention of the center, that is, to create a high-tech industrial base with strong technological innovation capabilities, high product technology, and strong industry characteristics. I wish them success in the cooperation!”